Viatris Pushes Back ‘Roadmap’ Reveal
Investor Event To Unveil Detailed Strategy Had Been Planned For 7 January
Executive Summary
Viatris has delayed the big reveal of details of its two-phase strategic roadmap that had been due to take place at an investor event planned for early January.
You may also be interested in...
Biocon Pays $3.3bn For Viatris Biosimilars Business
Biocon Biologics will pay up to $3.3bn to acquire the global biosimilars business of Viatris, in a long-rumored deal that will create a vertically-integrated biosimilars giant with annual sales approaching $1bn.
What’s Next? Five Things To Look Out For In February
In February, key launches from Accord and Eagle are set to go ahead, while Viatris will host its delayed investor day and industry will meet in-person in Florida for the US Association for Accessible Medicines’ Access! event.
Deal Watch: Roche, Pfizer, GSK Close Out 2021 With Licensing Transactions
Ahead of the usual flurry of deal-making in January, Roche gets retinal cell therapy candidate from Lineage Cell Therapeutics, Pfizer subsidiary Amplyx licenses antiviral candidate to Vera, and GSK expands neurology tie-up with Ligand.